Program

microscope-275984_1280

BARCELONA SEPTEMBER 20-21

AUDITORIUM. BELLVITGE UNIVERSITY HOSPITAL

An international meeting to introduce Oncobell, a new cancer research program within the Bellvitge Biomedical Research Institute (IDIBELL).

0000

Thursday 20th

09.00h – 09.45h

REGISTRATION

09.45h – 10.00h

WELCOME

10.00h – 10.50h

KEYNOTE LECTURE: 

Chaired by: Ramón Salazar, IDIBELL, Barcelona, Spain.

Exploiting vulnerabilities of drug-resistant cancer. 

René Bernards, NKI, Amsterdam, Netherlands.

11.00h – 11.20h

COFFEE BREAK

11.20h – 13.40h 

BRISTOL-MYERS SQUIBB SESSION: CLINICAL RESEARCH 

Chaired by: Josep Mª Piulats, IDIBELL, Barcelona, Spain.

The Impact of the Check Point Inhibition Strategies in the Treatment of Hematological Malignancies.

Eva Domingo-Domènech, IDIBELL, Barcelona, Spain.

Harnessing the personalized antitumor T-cell response to treat cancer.

Alena Gros, VHIO, Barcelona, Spain.

Potential and limitations of oncolytic adenoviruses.

Ramón Alemany, IDIBELL,  Barcelona, Spain.

Developping a CART19 under “academic conditions”.  How far can we drive it?

Manel Juan,    Hospital Clínic,  Barcelona, Spain.

13.40h – 14.40h

LUNCH

14.40h – 17.00h

GENETICS OF CANCER 

Chaired by: Laura Valle, IDIBELL, Barcelona, Spain.

Genetic susceptibility of colorectal cancer.

Victor Moreno, IDIBELL, Barcelona, Spain.

Clinical impact of genomic studies in chronic lymphocytic leukemia.

Elías Campo, IDIBAPS, Barcelona, Spain.

The challenge of interpreting variants of unknown significance.

Gabriel Capellà, IDIBELL, Barcelona, Spain.

Cross-species analysis of gene regulatory networks in metastatic prostate cancer

Àlvaro Aytes, IDIBELL, Barcelona, Spain.

0000

Friday 21st

09.00h – 11.20h

TARGETING OF SIGNALING PATHWAYS

Chaired by: Cristina Muñoz-Pinedo, IDIBELL, Barcelona, Spain. 

Insights into mechanisms of prostate cancer resistance.

Mark Rubin, Bern Univ, Switzerland.

Immune evasion and metastasis in colorectal cancer.

Eduard Batlle, IRBB, Barcelona, Spain.

The rationale for targeting TGF-beta in hepatocellular carcinoma.

Isabel Fabregat, IDIBELL, Barcelona, Spain.

Targeting the IRBC in c-Myc driven tumors. 

George Thomas, IDIBELL, Barcelona, Spain.

11.20h – 12.20h

POSTER SESSION  and  COFFE BREAK

12.20h – 13.20h

POSTERS HIGHLIGHTS  

The immune response: radio- and immuno-therapy.  Miguel Angel Berenguer, IDIBELL.

Liquid Biopsis.  Gabriel Capellà, IDIBELL.

Experimental therapeutics.  Ernest Nadal, IDIBELL.

Other topics will be considered. 

13.20h – 14.10h

KEYNOTE LECTURE:

Chaired by Oriol Casanovas, IDIELL, Barcelona, Spain.

Epigenetic signaling pathways controlling invasion and metastasis.

Douglas Hanahan, ISREC, Lausanne, Switzerland.

14.10h – 15.00h

LUNCH

15.00h – 16.45h

DRUG RESISTANCE AND MICROENVIRONMENT 

Chaired by: Mariona Graupera, IDIBELL.

LIF and the innate immune response. Linking embryology and cancer.

Joan Seoane, VHIO, Barcelona, Spain.

Resistance to Antiangiogenic Therapies by Metabolic Escape via Nucleotide Catabolism.

Oriol Casanovas, IDIBELL, Barcelona, Spain.

Understanding sarcomas: a path to a successful treatment.

Òscar Martinez-Tirado, IDIBELL, Barcelona, Spain. 

 

16.45h – 17.35h

RAMÓN ARECES LECTURE: 

Chaire by George Thomas, IDIBELL, Barcelona, Spain.

Cell Signaling by Receptor Tyrosine Kinases; From Basic Principles to Cancer Therapy.

Joseph Schlessinger, Yale University, New Haven, USA.

17.35h – 17.45h

CLOSING REMARKS

0000